MGC026 Shows 27% Response Rate in Heavily Pretreated Head and Neck Cancer; Front-Line Pembro Combo Study Planned
MGNX has more than doubled off its 52-week low of $1.29.
Summary
Interim Phase 1 data for MGC026, a B7-H3-directed ADC, showed a 27% best overall response rate (6/22, including four confirmed and two unconfirmed partial responses) in recurrent/metastatic SCCHN patients who had a median of three prior lines of therapy. In the dose-escalation group of 17 response-evaluable patients across 10 tumor types, confirmed ORR was 29% (5/17) with a median duration of response of 10.2 months. Safety looks manageable for the class: no interstitial lung disease, pneumonitis or ocular toxicity, no Grade 5 events, and no SCCHN discontinuations from treatment-related adverse events, though Grade ≥3 TRAEs hit 48% of SCCHN patients, led by anemia (30%) and neutropenia (26%). MacroGenics plans to start a front-line PD-L1-positive SCCHN cohort combining MGC026 with pembrolizumab in early 2027, with updated Phase 1 data expected mid-2027. For a clinical-stage company this size, positive durability data on a lead ADC is the kind of news that resets the pipeline story — the response is the stock's read on whether MGC026 can carry the program after the CDMO divestiture left the balance sheet as the main asset.
At the time of this announcement, MGNX was trading at $3.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231.2M. The 52-week trading range was $1.29 to $5.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.